Over the past five years, investor money is increasingly moving towards consumer software and later-stage life science ventures.
from @ Health and Medical News http://ift.tt/1CdBT6T
via Health and Medical NewsHealth and Medical News Pfizer Inc has already had its takeover overtures rebuffed three times by rival AstraZeneca Plc, but investors in the U.S. drugmaker say it can tolerate a little more rejection before going hostile with the deal. AstraZeneca turned down a sweeten...
from @ Health and Medical News http://ift.tt/1CdBT6T
via Health and Medical NewsHealth and Medical News Pfizer Inc has already had its takeover overtures rebuffed three times by rival AstraZeneca Plc, but investors in the U.S. drugmaker say it can tolerate a little more rejection before going hostile with the deal. AstraZeneca turned down a sweeten...
